INTRODUCTION
Hepatitis C virus (HCV) infection is a leading cause of morbidity and mortality worldwide, with a mortality rate that currently surpasses that of immunodeficiency virus infections [1] [2] . As expected, several longitudinal studies showed that the mortality rate of patients with chronic hepatitis C (CHC) is higher compared to that of uninfected subjects [3] [4] [5] . These studies also showed that CHC patients experience increases in both liver disease-and cardiovascular disease (CVD)-related mortality, although with contrasting results [4] [5] [6] [7] [8] . Consistent with these findings, clinical studies have shown a higher prevalence of metabolic disorders that are CVD risk factors, specifically type 2 diabetes mellitus (DM) [9] , insulin resistance [10] , and hepatic steatosis [11] , in HCV patients compared to uninfected controls. Moreover, recent data have identified HCV infection as a risk factor for subclinical [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and clinical cardiovascular alterations [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . However, the results of these published studies have been inconsistent, and the overall impact of HCV infection on CVDrelated morbidity and mortality is difficult to evaluate.
Considering the availability of new antiviral therapeutic strategies with increased effectiveness and excellent tolerability profiles, a definitive estimate of the impact of HCV infection on CVD-related risk is strongly needed [46] . Therefore, the aim of this meta-analysis was to estimate whether patients infected with HCV, compared to uninfected controls, evidenced increased rates of CVD-related mortality, carotid atherosclerosis, and cerebro-cardiovascular (CCV) events .
METHODS

Information sources and search strategies
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and/or the abstract: "cardiovascular disease," "cardiac outcomes," "heart," "heart disease," "cardiovascular mortality," "cardiac mortality," "atherosclerosis," "carotid atherosclerosis," "intima-media thickness," "myocardial infarction," "myocardial injury," "angina," "coronary disease," "congestive heart failure," "stroke," "transitory ischemic attack," "cerebrovascular disease," "cerebrovascular outcome," and "cardiovascular outcomes". Database searches were supplemented with literature searches of reference lists from potentially eligible articles by all the three reviewers (FSM, MM, and SP) to find additional studies.
Eligibility criteria
Studies were included in the meta-analysis if they compared the prevalence of CVD between HCVinfected subjects and uninfected controls, or if they compared the prevalence of HCV infection among subjects with different CVDs.
Searches
Among the 1,861 records identified through electronic search strategies, 596 duplicates and 1,227 irrelevant studies were excluded. Thirty-eight potentially relevant reports [4] [5] [6] [7] [8] [12] [13] [14] [15] [16] were identified and retrieved for detailed evaluation ( Figure 1 ). Among these, seven were excluded for inability to extract exact numbers of subjects and/or numbers of events from case and/or control groups [4, [13] [14] [15] 37, 42, 45] , eight were excluded for irrelevant data or absence of considered outcomes [12, 16, [38] [39] [40] [41] 43 ,44], and one was excluded for duplication bias [6] . The other 22 studies, all of which assessed the prevalence of CVDs relative to HCV status, met the inclusion criteria.
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selected 38 potentially eligible articles, and read each full report to identify the 22 studies included in the meta-analysis.
Data collection process
The studies were first reviewed by three reviewers (FSM, MM, and SP) using a list of predefined, pertinent issues that concerned the characteristics and outcomes of HCV-infected and uninfected groups. In some studies, HCV infection was defined based on the presence of anti-HCV only [5, 19, 21, 25, 27] , whereas the presence of both anti-HCV and HCV-RNA dictated HCV infection in other studies [7, 18, 20, [22] [23] [24] 26, 28, 29, [31] [32] [33] [34] [35] [36] . Two other studies defined HCV infection based on the presence of anti-HCV or HCV-RNA [8, 30] . When the data were available, patients from the HCV cohorts who either had a virological profile of an inactive infection (anti-HCV positive but HCV-RNA negative) [18, 35] or underwent antiviral therapy [29, 34] were excluded from the analysis.
Several study-and patient-level variables were extracted from all eligible studies and entered into a structured database. Study-level variables included the last name of the first author, publication year, country where the study was conducted, study design, number of subjects, and outcomes measured. Patient-level variables included the mean age, sex, race, cholesterol level, and body mass index (BMI) of patients, as well as the presence of hypertension, DM, obesity, and smoking habit among patients. Study quality was evaluated by the 9-star Newcastle-Ottawa Scale
[48], a validated technique for assessing the quality of nonrandomized studies in meta-analyses.
Discrepancies among reviewers about qualitative and quantitative data collection were infrequent (overall interobserver variation < 10%) and resolved by discussion.
Data synthesis
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Summary parameters were CVD-related mortality, carotid plaques, and CCV events, defined as ischemic stroke, myocardial infarction, angina, congestive heart failure, or transient ischemic attack.
Crude rates of CVD-related morbidity and mortality were retrieved in HCV-positive and HCVnegative individuals. The odds ratio (OR) was computed for each study by using the observed numbers of CVD cases and deaths.
Overall ORs and the corresponding 95% confidence intervals (CIs) of the frequencies of events in the HCV-positive and HCV-negative groups were calculated by the DerSimonian and
Laird random-effects model [49] , which accounts for both within-study variance and between-study heterogeneity. The random-effects model was used because we believe that the relevant variation in effects was a consequence of several interstudy differences. All statistical analyses were performed by Rev MAN [50] .
Two different methods were used to explore and explain the diversity among the results of different studies: subgroup analyses and meta-regression. A Chi-square (χ 2 ) test for interaction [51] was used to examine whether the cardiovascular risk associated with HCV infection varied significantly among subgroups.
We examined the extent to which differences in study outcomes could be explained by differences in characteristics at the patient level (i.e., age, sex, BMI, arterial hypertension, DM, high cholesterol/dyslipidemia, and smoking habit) or study level (i.e., publication year, geographical source of the study, design, study size, and quality). Several independent explanatory variables were included in univariate meta-regression models [52] . The dependent variable in the regression analyses was the logarithmic OR of cardiovascular risk in the HCV-positive vs. HCV-negative M A N U S C R I P T
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RESULTS
Characteristics of the studies
Main features of the studies included in the meta-analysis are shown in Table 1 When considering carotid atherosclerosis as an outcome, we included nine studies [18] [19] [20] [21] [22] [23] [24] [25] [26] that assessed the presence of carotid plaques. Seven of these studies [18] [19] [20] [21] [22] [23] [24] also examined intimamedia thickness (IMT). The nine studies collectively enrolled 9,083 patients, and the sample size of each cohort ranged from 72 to 4,784 subjects. The prevalence of HCV infection varied greatly (1.2-10.5%). There were four studies performed in European cohorts, two in Asiatic cohorts, two in African cohorts, and one in a U.S. cohort.
The search for CCV events as an outcome led to the inclusion of eight studies [27] [28] [29] [30] [31] [32] [33] 35] (six cohort and two case-control studies), which together enrolled 390,602 patients. The sample size of each cohort ranged from 582 to 171,665 subjects. The prevalence of HCV infection among the studies varied from 6.2% to 9.6%. Six studies were performed on U.S. or European cohorts, whereas two studies were performed on Asiatic populations. Two studies [34, 36] were not considered in the overall analysis of CCV events due to duplication bias [29, 30] , but were included in subanalyses of cardiovascular or cerebrovascular events alone.
Cardiovascular-related mortality and HCV infection
Three cohort studies (68,365 patients, 735 deaths) examined the effect of HCV infection on CVDrelated mortality ( Figure 2 ). Two studies [5, 7] reported a significantly higher mortality rate in HCV-M A N U S C R I P T
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infected patients compared to uninfected controls. The third study [8] did not show any effect. The pooled estimate of the effect of HCV infection was significant (OR 1.65, 95% CI 1.07-2.56, P = 0.02) with a significant heterogeneity (I 2 = 76%, P = 0.02). Univariate regression analyses showed that CVD-related mortality was not significantly affected by the geographical source of the study (West vs. non-West) or study quality (both variables were available in all three studies; Table 2 ).
Other potential patient-level covariates (i.e., well-known cardiovascular risk factors) were not available in all three studies.
Carotid atherosclerosis and HCV infection
Nine case-control studies (9,083 patients in total, 1,979 patients with carotid plaques) examined the effect of HCV infection on carotid plaques ( Figure 3A ). HCV infection favored the presence of carotid plaques in eight of the nine studies, but this difference was significant in only five studies.
The pooled estimate of the effect of HCV infection was significant (OR 2.27, 95% CI 1.76-2.94, P < 0.001), without significant heterogeneity (I 2 = 31%, P = 0.17).
Univariate regression analyses of seven studies showed that the impact of HCV infection on the presence of carotid plaques was directly affected by smoking status (P = 0.02; Table 2 ). The pooled OR for this relationship was 2.66 (95% CI 1.96-3.61, P < 0.001) in populations with a high prevalence of smoking (>20%) [54] compared to 1.07 (95% CI 0.57-2.01, P = 0.84) in populations with a low prevalence of smoking (<20%) [54] , with a significant interaction (χ 2 = 6.45; P = 0.01, Figure 3B ). Seven case-control studies (3,749 patients) were considered in terms of the impact of HCV infection on IMT (Supplemental Material 1). We observed a significant pooled estimate (mean difference 0.09, 95% CI 0.03-0.16, P < 0.001), albeit in the presence of heterogeneity (I 2 = 90%; P = 0.007; Supplemental Figure 1 ), similar to the results of the analysis of carotid plaques.
Cerebro-cardiovascular events and HCV infection
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The effect of HCV infection on CCV events was evaluated in eight studies (390,602 patients in total, 18,388 events; Figure 4A ). Although HCV infection had a significant impact on CVD-related morbidity in five of the eight studies, three studies showed a decrease in the number of CCV events.
The pooled estimate of the effect of HCV infection on CCV events was significant (OR 1.30, 95% CI 1.10-1.55, P = 0.002) but had significant heterogeneity (I 2 = 91%, P < 0.001). Upon separating CCV into cerebrovascular or cardiovascular events, we confirmed that HCV infection was associated with both cardiovascular (OR 1.20, 95% CI 1.03-1.40; P = 0.02; Supplemental Figure   2A ) and cerebrovascular (OR 1.35, 95% CI 1.00-1.82, P = 0.05; Supplemental Figure 2B ) events.
Univariate regression analyses showed that the impact of HCV infection on CCV risk was higher in cohort studies (P = 0.01), studies of older patients (P < 0.001), and studies with a higher prevalence of hypertension (P = 0.008) or DM (P < 0.001; for studies with a prevalence < 10%, with a significant interaction (χ 2 = 22.48, P < 0.001; Figure   4B ). Among studies that reported the prevalence of hypertension, the pooled OR was significant for studies with a prevalence > 20% (OR 1.71, 95% CI 1.32-2.23, P < 0.001) but not for those with a prevalence < 20% (OR 1.00, 95% CI 0.72-1.40; P = 1.00) with a significant interaction (χ 2 = 6.21, P = 0.01; Figure 4C ). The pooled OR was 1.21 (95% CI 1.05-1.39, P = 0.008) for cohort studies and 2.01 (95% CI 0.31-13.04, P = 0.46) for case-control studies, without a significant interaction (χ 2 = 0.28, P = 0.60; Figure 4D ). The pooled OR was 2.46 (95% CI 0.60-10.16; P = 0.21) for studies with a mean population age > 50 years and 1.35 (95% CI 0.97-1.88, P = 0.07) for those with a mean population age < 50 years, without a significant interaction (χ 2 = 0.65, P = 0.42; Figure   4E ).
Finally, the Egger test for publication bias showed no significant risk of having missed or overlooked studies in terms of overall mortality (P = 0.385), CCV events (P = 0.682), carotid atherosclerosis (P = 0.831), or IMT (P = 0.357).
DISCUSSION
This meta-analysis of aggregate data from 22 studies shows that compared to uninfected controls, HCV-infected individuals have increased risks of CVD-related mortality and subclinical carotid atherosclerosis. We observed a slightly significant increase in CCV events among HCV-infected patients, despite the high heterogeneity among studies that was mostly related to the prevalence of DM and hypertension.
Historically, HCV infection has been considered to affect only the liver, via the development of cirrhosis and its complications. HCV infection has also been shown to increase the risk of overall We found a two-fold higher risk of subclinical carotid plaques among HCV-infected individuals compared to uninfected controls, without significant heterogeneity among studies, as well as an increased risk of carotid thickening in HCV-infected subjects. These findings, which are in agreement with our now reported increased risk of CVD-related mortality among HCV-infected individuals, add relevant data to the debated issue of atherosclerosis and HCV infection [13] [14] [15] [18] [19] [20] [21] [22] [23] [24] [25] [26] . Our data suggest that HCV infection is another risk factor for carotid atherosclerosis, and that this association is affected by the smoking habit in populations with a high prevalence of smokers.
However, the small number of patients in studied populations with a low prevalence of smokers limits the strength of this conclusion.
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Another recently debated issue regards the potential association between HCV infection and CCV events. Some studies in the literature have reported that HCV infection is a risk factor of CCV events, whereas others have reported a protective effect of infection [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . In our meta-analysis, we found a significant increase in the overall risk of CCV events among HCV-infected individuals compared to uninfected controls. As expected, we also found a high heterogeneity among the studies. Therefore, we performed further analyses to identify groups of patients in whom the effect of the infection was either pronounced or lacking. Nevertheless, our subgroup analyses were unable to explain the observed heterogeneity fully, and the association of HCV infection remained significant in populations with a higher prevalence of cardiovascular risk factors, DM, or hypertension. Our data agree with those of Hsu and colleagues [43] , who recently showed that the risk of peripheral artery disease is higher in HCV-infected patients than in uninfected patients, and that this risk further increases with the presence of comorbidities.
Although our meta-analysis was not designed to explore the reasons for the association between HCV infection and increased cardiovascular risk, some hypotheses can be proposed The results of this meta-analysis are subject to several limitations, such as differences in the nature of the control groups among the different studies. We attempted to control for these M A N U S C R I P T
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differences by including patient-and study-level covariates. However, there were likely other potentially important confounders for which we did not control and that might have affected the results. Furthermore, the results only describe variations between studies, and not between patients, because they reflect group averages rather than individual data. More detailed comparisons could be achieved with meta-analyses of individual patient data. Lack of data on the severity of liver fibrosis, a factor associated with the severity of cardiovascular alterations in CHC [17, 23] and nonalcoholic fatty liver disease [58,59], could affect the accuracy of the results.
With our extensive computer search for studies, we are confident that no important published trials were overlooked. Publication bias was not substantial and was considered unlikely to change the direction of our pooled estimates of observed HCV effects. Although issues of quality assessment may be somewhat important in this review, the quality of the individual studies did not seem to bias the results of our meta-analysis.
The available evidence is sufficient to conclude that HCV infection increases cardiovascular risk, including risks of subclinical carotid atherosclerosis, CCV events, and cardiovascular mortality. Furthermore, the effect of HCV infection on cardiovascular risk appears to be especially pronounced in populations with a high prevalence of smoking, hypertension, or DM. We assumed as secondary outcome the mean difference of intima media thickening between HCV positive and HCV negative subjects. The variance for each study was calculated by computing the pooled standard deviation of the intima media thickening between the HCV positive and negative groups. For the computation of pooled effects, each study was assigned a weight consisting of the reciprocal of its variance. Estimates of the pooled exposure effect and 95% confidence intervals were calculated with models based on the random effects assumptions. 
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